Works by Tempero, M A

Results: 13

Nerve Growth Factor Regulates Neurolymphatic Remodeling during Corneal Inflammation and Resolution.

Published in:

PLoS ONE, 2014, v. 9, n. 11, p. 1, doi. 10.1371/journal.pone.0112737

By:

Fink, Darci M.;
Connor, Alicia L.;
Kelley, Philip M.;
Steele, Maria M.;
Hollingsworth, Michael A.;
Tempero, Richard M.

Publication type:

Article

Invariant asymmetry renews the lymphatic vasculature during homeostasis.

Published in:

2016

By:

Connor, Alicia L.;
Kelley, Philip M.;
Tempero, Richard M.

Publication type:

journal article

Thrombocytopenia and laboratory evidence of disseminated intravascular coagulation after shunts for ascites in malignant disease.

Published in:

1985

By:

Tempero, Margaret A.;
Davis, Richard B.;
Reed, Elizabeth;
Edney, James;
Tempero, M A;
Davis, R B;
Reed, E;
Edney, J

Publication type:

journal article

Fatal pulmonary toxicity resulting from treatment with gemcitabine.

Published in:

1998

By:

Tempero, Margaret A.;
Brand, Randall;
Tempero, M A;
Brand, R

Publication type:

Case Study

MUC1‐specific anti‐tumor responses: molecular requirements for CD4‐mediated responses.

Published in:

International Immunology, 2002, v. 14, n. 8, p. 873, doi. 10.1093/intimm/dxf053

By:

VanLith, Michelle L.;
Kohlgraf, Karl G.;
Sivinski, Connie L.;
Tempero, Richard M.;
Hollingsworth, Michael A.

Publication type:

Article

Influence of organ site and tumor cell type on MUC1-specific tumor immunity.

Published in:

International Immunology, 2001, v. 13, n. 2, p. 233, doi. 10.1093/intimm/13.2.233

By:

Morikane, Keita;
Tempero, Richard M.;
Sivinski, Connie L.;
Kitajima, Shimichi;
Gendler, Sandra J.;
Hollingsworth, Michael A.

Publication type:

Article

Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.

Published in:

Cancer Immunology, Immunotherapy, 2002, v. 51, n. 6, p. 327, doi. 10.1007/s00262-002-0277-3

By:

Sivinski, Connie L.;
Kohlgraf, Karl G.;
VanLith, Michelle L.;
Morikane, Keita;
Tempero, Richard M.;
Hollingsworth, Michael A.

Publication type:

Article

Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice.

Published in:

International Journal of Cancer, 1999, v. 80, n. 4, p. 595, doi. 10.1002/(SICI)1097-0215(19990209)80:4<595::AID-IJC18>3.0.CO;2-B

By:

Tempero, Richard M.;
Rowse, Gerald J.;
Gendler, Sandra J.;
Hollingsworth, Michael A.

Publication type:

Article

Lymphatic malformations: Review of current treatment

Published in:

Otolaryngology-Head & Neck Surgery, 2010, v. 142, n. 6, p. 795, doi. 10.1016/j.otohns.2010.02.026

By:

Perkins, Jonathan A.;
Manning, Scott C.;
Tempero, Richard M.;
Cunningham, Michael J.;
Edmonds, Joseph L.;
Hoffer, Fredric A.;
Egbert, Mark A.

Publication type:

Article

Lymphatic malformations: Current cellular and clinical investigations

Published in:

Otolaryngology-Head & Neck Surgery, 2010, v. 142, n. 6, p. 789, doi. 10.1016/j.otohns.2010.02.025

By:

Perkins, Jonathan A.;
Manning, Scott C.;
Tempero, Richard M.;
Cunningham, Michael J.;
Edmonds, Joseph L.;
Hoffer, Fredric A.;
Egbert, Mark A.

Publication type:

Article

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.

Published in:

British Journal of Cancer, 2013, v. 109, n. 7, p. 1725, doi. 10.1038/bjc.2013.553

By:

Kelley, R K;
Hwang, J;
Magbanua, M J M;
Watt, L;
Beumer, J H;
Christner, S M;
Baruchel, S;
Wu, B;
Fong, L;
Yeh, B M;
Moore, A P;
Ko, A H;
Korn, W M;
Rajpal, S;
Park, J W;
Tempero, M A;
Venook, A P;
Bergsland, E K

Publication type:

Article

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.

Published in:

British Journal of Cancer, 2013, v. 109, n. 4, p. 920, doi. 10.1038/bjc.2013.408

By:

Ko, A H;
Tempero, M A;
Shan, Y-S;
Su, W-C;
Lin, Y-L;
Dito, E;
Ong, A;
Wang, Y-W;
Yeh, C G;
Chen, L-T

Publication type:

Article

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.

Published in:

British Journal of Cancer, 2005, v. 93, n. 2, p. 195, doi. 10.1038/sj.bjc.6602687

By:

Ko, A. H.;
Hwang, J.;
Venook, A. P.;
Abbruzzese, J. L.;
Bergsland, E. K.;
Tempero, M. A.

Publication type:

Article